Domixtar Acquired by Azzurra Capital and TCD
Deal News | Aug 07, 2025 | Finance Community IT - 3 Private Equity
Azzurra Capital and The Club Dealers have signed a binding contract to acquire 100% of Domixtar Pharmaceutical from Alto Partners and Trilantic Europe. Domixtar, an Italian player in the Contract Development and Manufacturing Organization (CDMO) sector, will retain its management team, led by Maurizio Silvestri, which will invest alongside the buyers. The buyers were advised by Legance for legal aspects, Alvarez & Marsal for financial due diligence, Andersen for tax due diligence, Fortlane Partners for commercial due diligence, ERM for ESG due diligence, and WTW for insurance due diligence. The sellers were advised by Houlihan Lokey, LMCR Studio Legale, and Foglia & Partners. Domixtar was formed in 2024 from the merger of Mipharm and Doppel. Under its new ownership, the group aims to grow through organic expansion and strategic acquisitions, harnessing its high profitability and a solid management team.
Sectors
- Pharmaceuticals and Biotechnology
- Private Equity and Investment
Geography
- Italy – Domixtar Pharmaceutical is an Italian company with four production plants in regions such as Milan, implying significant national relevance.
- Europe – Both the acquiring and selling parties operate within Europe, and Domixtar's client base includes major European pharmaceutical companies.
Industry
- Pharmaceuticals and Biotechnology – Domixtar Pharmaceutical is integral to the pharmaceuticals industry as a Contract Development and Manufacturing Organization (CDMO), focusing on producing liquid, solid, and semisolid drug forms.
- Private Equity and Investment – The acquisition of Domixtar by Azzurra Capital and The Club Dealers highlights the role of private equity in fostering growth for mid-sized companies in the healthcare sector.
Financials
- 170,000,000 – Estimated revenue of Domixtar Pharmaceutical for the year 2025 in euros.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Domixtar Pharmaceutical | Target Company | Company | Domixtar is a CDMO, formed in 2024 from the merger of Mipharm and Doppel, focusing on drug development and manufacturing. |
| Alto Partners | Selling Company | Company | Alto Partners is one of the former owners of Domixtar Pharmaceutical. |
| Trilantic Europe | Selling Company | Company | Trilantic Europe is one of the investment firms selling their stake in Domixtar Pharmaceutical. |
| Azzurra Capital | Buyer | Company | Azzurra Capital is a private equity firm acquiring Domixtar Pharmaceutical. |
| The Club Dealers (TCD) | Buyer | Company | The Club Dealers is a private equity firm involved in the acquisition of Domixtar Pharmaceutical. |
| Legance | Legal Advisor to Buyers | Company | Provided legal counsel to Azzurra Capital and The Club Dealers for the acquisition. |
| Alvarez & Marsal | Financial Due Diligence Advisor | Company | Conducted the financial due diligence for the acquiring parties. |
| Andersen | Tax Due Diligence & Structuring Advisor | Company | Handled tax due diligence for Azzurra Capital and The Club Dealers. |
| Fortlane Partners | Commercial Due Diligence Advisor | Company | Conducted the commercial due diligence for the acquisition. |
| ERM | ESG Due Diligence Advisor | Company | Conducted ESG due diligence for the buyers. |
| WTW (Willis Towers Watson) | Insurance Due Diligence Advisor | Company | Provided insurance due diligence services for the acquisition. |
| Houlihan Lokey | Financial Advisor to Sellers | Company | Acted as financial advisor for the selling companies in the transaction. |
| LMCR Studio Legale | Legal Advisor to Sellers | Company | Provided legal advice to the selling shareholders in the transaction. |
| Foglia & Partners | Tax Advisor to Sellers | Company | Handled tax advisory services for the vendors during the sale process. |
| Maurizio Silvestri | Management | Person | President and Executive Chairman of Domixtar Pharmaceutical, continuing to lead post-acquisition. |